IUPAC: 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine · C17H20N4S · MW 312.44 g/mol · CAS 132539-06-1
Olanzapine (Zyprexa, LY170053). Second-generation "atypical" antipsychotic of the thienobenzodiazepine class — a close structural cousin of clozapine. Not a receptor scalpel but a shotgun: a genuinely multi-receptor antagonist that hits D2, 5-HT2A, 5-HT2C, H1, muscarinic M1–5 and α1 all in the low-nanomolar range. Broad efficacy across schizophrenia, bipolar mania and (with fluoxetine) bipolar depression — bought at the price of the worst metabolic profile in the class outside clozapine. Trade names: Zyprexa, Zyprexa Zydis, Zyprexa Relprevv (pamoate depot), Zalasta, component of Symbyax and Lybalvi.
Olanzapine is an antagonist / inverse agonist at a broad panel of aminergic GPCRs. The antipsychotic effect is driven by post-synaptic D2 dopamine receptor blockade in the mesolimbic pathway (Ki ~20 nM, ChEMBL), which dampens the aberrant salience that underlies positive symptoms — hallucinations, delusions. What makes it "atypical" is that D2 occupancy is accompanied by even tighter 5-HT2A antagonism (Ki ~2 nM, ChEMBL): the 5-HT2A:D2 affinity ratio (Meltzer's index) disinhibits nigrostriatal and tuberoinfundibular dopamine, sparing the extrapyramidal side effects and severe hyperprolactinemia that define the older butyrophenones.
Unlike the transporter-blocking antidepressants or the GPCR agonist psychedelics, olanzapine engages no orthosteric agonism — it occupies the aminergic pocket and holds these receptors in their inactive conformation. The trouble is that the same pocket is conserved across the histaminergic, cholinergic and adrenergic families, so olanzapine binds all of them with high affinity. That promiscuity is the drug: it is both the source of its broad clinical utility and the engine of its side-effect burden.
Mesolimbic D2 blockade (Ki ~20 nM) is the antipsychotic mechanism. Olanzapine achieves the ~65–80% striatal occupancy window needed for efficacy at therapeutic doses, but dissociates faster than haloperidol — "loose binding" that contributes to low EPS.
Highest-affinity target (Ki ~2 nM). Cortical 5-HT2A blockade drives the "atypia": it enhances prefrontal dopamine release and buffers nigrostriatal D2 blockade, reducing parkinsonism, dystonia and tardive risk relative to typical agents.
Very high affinity (Ki ~2.8 nM). Central H1 antagonism produces sedation and — via hypothalamic AMPK activation — is a primary driver of appetite stimulation and weight gain. This is a signature liability, not an incidental one.
High affinity (Ki ~7 nM). 5-HT2C blockade in the arcuate nucleus disinhibits orexigenic NPY/AgRP neurons. H1 + 5-HT2C co-antagonism is the two-hit combination that best predicts antipsychotic-induced weight gain.
Broad anticholinergic activity (M1 Ki ~4.7 nM). Contributes dry mouth, constipation, blurred vision, tachycardia and cognitive blunting — but also self-shields against EPS. High antimuscarinic load is a delirium/overheating risk in the elderly.
Moderate α1 blockade (Ki ~60 nM) produces orthostatic hypotension, reflex tachycardia and dizziness, most pronounced during dose titration. Compounds the fall risk in older patients already carrying anticholinergic and sedative burden.
The mechanistic irony is that the two receptors olanzapine hits hardest are not its therapeutic targets. H1 (~2.8 nM) and 5-HT2C (~7 nM) both bind tighter than D2 (~20 nM) — the receptor doing the actual antipsychotic work. The affinity hierarchy predicts the clinical picture: efficacy plus profound metabolic and sedative side effects.
Olanzapine is well absorbed and highly lipophilic, with a large volume of distribution (~1000 L) and a long half-life of ~30 h supporting convenient once-daily dosing and a ~1-week approach to steady state. It undergoes substantial first-pass metabolism (oral bioavailability ~60%) but the metabolites are pharmacologically inactive — clinical effect tracks the parent drug. Clearance is ~30–47% faster in smokers (CYP1A2 induction) and slower in women and the elderly, a real-world source of dose variability.
Metabolism cascade: Two parallel primary routes — direct N-glucuronidation and CYP1A2 oxidation — with a minor flavin-monooxygenase branch. All products are inactive and renally/biliary cleared.
The smoking interaction is clinically load-bearing. Tobacco smoke (polycyclic aromatic hydrocarbons, not nicotine) is a potent CYP1A2 inducer. Smokers can require substantially higher doses; conversely, a patient who stops smoking — including on inpatient admission to a smoke-free ward — can see plasma olanzapine rise sharply within days, precipitating sedation and toxicity. Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) raise levels the other direction and warrant dose reduction.
A long-acting intramuscular depot (olanzapine pamoate, Zyprexa Relprevv) exists but carries its own hazard: post-injection delirium/sedation syndrome (PDSS), an accidental partial intravascular delivery causing acute over-sedation and delirium, which mandates a 3-hour supervised observation period after every injection.
Olanzapine's receptor promiscuity maps onto anatomically distinct circuits. The therapeutic signal comes from two dopamine/serotonin pathways; the dose-limiting toxicity comes from a third, hypothalamic circuit and from the peripheral autonomic actions. Reading the drug as a set of parallel circuit effects explains why it is simultaneously one of the most effective antipsychotics and one of the most metabolically toxic.
Blockade of post-synaptic D2 receptors in the ventral striatum / nucleus accumbens attenuates the pathological dopamine signalling that generates delusions and hallucinations. Olanzapine reaches the therapeutic 65–80% D2 occupancy band at standard doses; it has consistently ranked among the more efficacious agents (CATIE, meta-analyses) with lower discontinuation for lack of effect — offset by discontinuation for weight gain.
5-HT2A antagonism (its highest-affinity action) increases prefrontal and nigrostriatal dopamine release, counterbalancing striatal D2 blockade. The net effect is a low rate of extrapyramidal symptoms and tardive dyskinesia at therapeutic doses, and only modest, transient prolactin elevation — because tuberoinfundibular D2 tone is partially preserved. This is the defining pharmacology of the second generation.
In the arcuate and paraventricular hypothalamus, H1 antagonism activates AMPK while 5-HT2C antagonism disinhibits orexigenic NPY/AgRP neurons and suppresses anorexigenic POMC signalling. The result is powerful hyperphagia, reduced satiety and lowered energy expenditure. Clinically this manifests as rapid, often large weight gain (frequently >7% of body weight), new-onset insulin resistance, dyslipidemia and type 2 diabetes — and, distinctively, diabetic ketoacidosis that can occur acutely and even independently of weight change.
Away from the CNS reward circuits, muscarinic blockade produces dry mouth, constipation (rarely severe ileus), urinary hesitancy and tachycardia; α1 blockade produces orthostatic hypotension and dizziness; H1 blockade produces daytime sedation. In older adults this triad compounds into falls, confusion and impaired thermoregulation — the reason olanzapine carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis.
Beyond schizophrenia and bipolar mania, olanzapine has robust off-label roles: as a highly effective antiemetic in chemotherapy-induced nausea and vomiting (5-HT3/D2/muscarinic actions), and — increasingly — in appetite stimulation and low-dose management of nausea in palliative care and anorexia nervosa, where the very weight-gain liability that limits its psychiatric use becomes the desired effect.
Olanzapine is a near-planar, rigid tricyclic scaffold — the fused thieno-benzodiazepine
core is conformationally locked, and the only meaningful degree of freedom is rotation of the
N-methylpiperazine appendage (the molecule has effectively zero rotatable bonds in its ring system,
heavy-atom count 22). In FlexAID∆S terms this means a very small ΔS_conf penalty on binding:
the ligand is pre-organized and pays almost no entropic price to dock, which is a large part of why a
single, modest-sized molecule can reach low-nanomolar Ki at six different aminergic receptors.
Each of those pockets — D2 (modelled here on PDB 6CM4), 5-HT2A, 5-HT2C,
H1, muscarinic and α1 — is a class-A GPCR orthosteric site that, in the apo state,
samples a wide ensemble of side-chain rotamers: high pocket Shannon entropy H_pocket.
Olanzapine's protonated piperazine nitrogen forms the canonical salt bridge to the conserved
Asp3.32, and the flat tricycle wedges against the aromatic cluster of TM5/TM6. Binding collapses
that rotameric ensemble into a single conformer — the entropy-collapse signature of a competitive
antagonist locking a flexible receptor closed. Because the pharmacophore (basic amine + lipophilic
aromatic cap) is conserved across the aminergic family, the same collapse fingerprint recurs at
each target: one rigid key, many similar locks.
Predicted ΔG_bind for the D2:olanzapine complex (tENCoM-informed, FlexAID∆S
ensemble) is approximately −10 to −10.6 kcal/mol, consistent with the observed
D2 Ki ~20 nM (theoretical ΔG = −RT·ln(Ka) ≈ −10.5 kcal/mol at 298 K), and roughly
−11.5 to −11.9 kcal/mol at 5-HT2A (Ki ~2 nM). The thermodynamic lesson is
that low conformational entropy loss is what buys promiscuity: a pre-rigidified scaffold that
collapses many pockets equally well is, by construction, a dirty drug — and olanzapine's side-effect
profile is that pharmacology, read off the receptorome instead of the clinic.
Olanzapine is an effective prescription medicine, not a recreational drug — but its toxicity is chronic, insidious and frequently undertreated. Non-moralistic, evidence-based: the risks below are monitorable and largely manageable with the right surveillance.
| Target | Affinity | Rel. | Action |
|---|---|---|---|
|
5-HT2A
Serotonin 2A (HTR2A)
|
Ki ≈ 2 nM
1.4 – 4 nM
|
Antagonist | |
|
H1
Histamine H1 (HRH1)
|
Ki ≈ 2.8 nM
1.2 – 10 nM
|
Inverse agonist | |
|
M1
Muscarinic ACh M1 (CHRM1)
|
Ki ≈ 4.7 nM
2.1 – 26 nM
|
Antagonist | |
|
5-HT2C
Serotonin 2C (HTR2C)
|
Ki ≈ 7 nM
2.8 – 14 nM
|
Antagonist | |
|
D2
Dopamine D2 (DRD2)
|
Ki ≈ 20 nM
2.1 – 78 nM
|
Antagonist | |
|
α1A
α1A-adrenergic (ADRA1A)
|
Ki ≈ 60 nM
PDSP / J Med Chem
|
Antagonist |